<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02326220</url>
  </required_header>
  <id_info>
    <org_study_id>R727-CL-1216</org_study_id>
    <nct_id>NCT02326220</nct_id>
  </id_info>
  <brief_title>Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy</brief_title>
  <acronym>ODYSSEY ESCAPE</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipid Apheresis Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the
      effect of alirocumab in comparison with placebo on the frequency of LDL apheresis treatments
      in patients with HeFH undergoing LDL apheresis therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of apheresis treatments during a 12-week period normalized by the number of planned apheresis treatments according to each patient's established schedule at screening</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) (pre-apheresis)</measure>
    <time_frame>Baseline to week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized rate of apheresis treatments during a 4-week period</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in apolipoprotein B (ApoB) (pre-apheresis) (pre-apheresis) to week 6</measure>
    <time_frame>Baseline to week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in non-high-density lipoprotein cholesterol (HDL-C) (pre-apheresis)</measure>
    <time_frame>Baseline to week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in total cholesterol (pre-apheresis)</measure>
    <time_frame>Baseline to week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in ApoA-1 (pre-apheresis)</measure>
    <time_frame>Baseline to week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ≥30% reduction in LDL-C (pre-apheresis)</measure>
    <time_frame>At week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ≥50% reduction in LDL-C (pre-apheresis)</measure>
    <time_frame>At week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in LDL-C (pre-apheresis)</measure>
    <time_frame>Baseline to week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in ApoB (pre-apheresis)</measure>
    <time_frame>Baseline to week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in non-HDL-C (pre-apheresis) to week 18</measure>
    <time_frame>baseline to week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in total cholesterol (pre-apheresis) to week 18</measure>
    <time_frame>baseline to week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in ApoA-1(pre-apheresis) to week 18</measure>
    <time_frame>baseline to week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ≥30% reduction in LDL-C (pre-apheresis) at week 18 (pre-apheresis)</measure>
    <time_frame>At week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ≥50% reduction in LDL-C (pre-apheresis) at week 18</measure>
    <time_frame>At week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of W-BQ22 (Well-Being Questionnaire 22-item version) from baseline to week 18</measure>
    <time_frame>Baseline to week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in lipoprotein (a) [Lp(a)] (pre-apheresis)</measure>
    <time_frame>Baseline to week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in HDL-C (pre-apheresis)</measure>
    <time_frame>Baseline to week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in triglyceride (TG) levels (pre-apheresis)</measure>
    <time_frame>Baseline to week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Lp(a) (pre-apheresis) to week 18</measure>
    <time_frame>Baseline to week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in HDL-C (pre-apheresis) to week 18</measure>
    <time_frame>Baseline to week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in TG levels (pre-apheresis) to week 18</measure>
    <time_frame>Baseline to week 18</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Heterozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Alirocumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alirocumab subcutaneous (SC) dose regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching alirocumab subcutaneous (SC) dose regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alirocumab</intervention_name>
    <arm_group_label>Alirocumab</arm_group_label>
    <other_name>REGN727</other_name>
    <other_name>SAR236553</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women ≥18 years of age at the time of the screening visit

          2. Diagnosis of HeFH (Heterozygous familial hypercholesterolemia)

          3. Currently undergoing LDL (low-density lipoprotein) apheresis therapy QW (weekly) or
             Q2W (every 2 weeks) or at least 8 weeks prior to the screening visit

        Exclusion Criteria:

          1. Homozygous FH (familial hypercholesterolemia)

          2. Background medical LMT (lipid-modifying therapy) (if applicable) that has not been
             stable for at least 8 weeks prior to the screening visit

          3. LDL apheresis schedule/ apheresis settings that have not been stable for at least 8
             weeks prior to the screening visit

          4. An LDL apheresis schedule other than QW to Q2W

          5. Initiation of a new exercise program or exercise that has not remained stable within 8
             weeks prior to the screening visit (week -2)

          6. Initiation of a new diet or a diet that has not been stable within 8 weeks prior to
             the screening visit (week -2)

          7. Use of nutraceuticals or over-the-counter therapies known to affect lipids, at a
             dose/amount that has not been stable for at least 8 weeks prior to the screening visit
             (week -2), or between the screening and randomization visit

          8. Presence of any clinically significant uncontrolled endocrine disease known to
             influence serum lipids or lipoproteins

          9. Known history of a positive test for human immunodeficiency virus

         10. Use of any active investigational drugs within 1 month or 5 half-lives of screening,
             whichever is longer

         11. Patients who have been treated with at least 1 dose of alirocumab or any other
             anti-PCSK9 monoclonal antibody in any other clinical studies

         12. Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goettlinger</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muenchen (2 locations)</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Passau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Moriarty PM, Parhofer KG, Babirak SP, Cornier MA, Duell PB, Hohenstein B, Leebmann J, Ramlow W, Schettler V, Simha V, Steinhagen-Thiessen E, Thompson PD, Vogt A, von Stritzky B, Du Y, Manvelian G. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J. 2016 Dec 21;37(48):3588-3595. doi: 10.1093/eurheartj/ehw388. Epub 2016 Aug 29.</citation>
    <PMID>27572070</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2014</study_first_submitted>
  <study_first_submitted_qc>December 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2014</study_first_posted>
  <disposition_first_submitted>January 20, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>January 20, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 23, 2017</disposition_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

